Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data For Patients Suffering From Skin Cancer

Sun Pharma has announced that the company has presented Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data to treat patients suffering from Skin Cancer. The company has presented these data analysis at the Virtual Meeting of the American Academy of Dermatology (AAD). These virtual meetings are to be scheduled on June 12-14, 2020.

Skin Cancer is widely regarded as the most common type of cancer and it is commonly known as the nonmelanoma Skin cancers. It is expected that the Skin Cancer affected more than 4 million US citizens each year, a rate that has doubled in the last 5 decades. This cancer is 100% curable, only treated properly.

Senior Medical Director of Sun Pharma. Nicholas Squittieri, M.D., said “With incidence rates increasing and more treatment options needed, we are committed to providing clinical support for our medicines and helping address the needs of patients who are impacted by the different stages of skin cancer.”

“The evidence presented at the AAD Virtual Meeting Experience offers important insights and guidance to dermatology healthcare providers who are using ODOMZO and LEVULAN in their daily clinical practice,” Nicholas Squittieri further added.

Vice-Chairman of the Department of Dermatology, University Hospital of Zurich, Switzerland, Prof. Reinhard Dummer, M.D., said, “Our research showed that the positive efficacy and safety benefits of ODOMZO were not impacted by commonly used medicines like statins or nonsteroidal anti-inflammatory drugs that some patients may need to take simultaneously to treat other health conditions.”

“Since basal cell carcinoma is more commonly found in older adults, these insights are reassuring for dermatologists who are considering ODOMZO for their older patients,” Vice-Chairman of the Department of Dermatology, University Hospital of Zurich, Switzerland, Prof. Reinhard Dummer further added.

Leave a Reply

Your email address will not be published. Required fields are marked *